MGNX
MacroGenics, Inc.
Price Chart
Latest Quote
$4.78
+0.09 (+1.92%)
Current Price
| Previous Close | $4.69 |
| Open | $4.70 |
| Day High | $5.08 |
| Day Low | $4.56 |
| Volume | 1,941,373 |
Stock Information
| Shares Outstanding | 63.56M |
| Total Debt | $36.51M |
| Cash Equivalents | $154.23M |
| Revenue | $157.08M |
| Net Income | $-70.36M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $303.83M |
| EPS (TTM) | $-1.11 |
| Exchange | NMS |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $185.16M |
| Sales | $157.08M |
| Income | $-70.36M |
| Book/sh | $0.33 |
| Cash/sh | $2.43 |
| Employees | 293 |
Financial Ratios
| Quick Ratio | 1.72 |
| Current Ratio | 1.90 |
| Debt/Eq | 172.23 |
Returns & Margins
| ROA | -17.98% |
| ROE | -140.27% |
| Gross Margin | -16.24% |
| Operating Margin | -160.96% |
| Profit Margin | -44.79% |
Ownership
| Insider Ownership | 3.43% |
| Institutional Ownership | 70.27% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -3.38 |
| P/S | 1.93 |
| P/B | 14.31 |
Analyst Data
| Recommendation | none |
| Target Price | $6.75 |
Technical Indicators
| SMA20 | $4.15 |
| SMA50 | $3.78 |
| SMA200 | $2.37 |
| RSI | 64.50 |
| ATR | 0.3111 |
| Shares Float | 52.40M |
| Short Float | 8.12% |
| Short Ratio | 3.46 |
| Volatility | 1.20 |
| Rel Volume | 2.48 |
Performance History
| Week | +23.20% |
| Month | +5.52% |
| Quarter | +75.09% |
| 6 Months | +218.67% |
| YTD | +196.89% |
| Year | +262.12% |
| 3 Years | -21.90% |
| 5 Years | -77.09% |
| 10 Years | -79.26% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-24 | $4.78 | 1,941,373 |
| 2026-06-23 | $4.69 | 1,490,600 |
| 2026-06-22 | $4.58 | 2,039,900 |
| 2026-06-18 | $4.13 | 973,000 |
| 2026-06-17 | $3.96 | 649,600 |
| 2026-06-16 | $3.88 | 548,300 |
| 2026-06-15 | $4.13 | 620,500 |
| 2026-06-12 | $3.96 | 513,200 |
| 2026-06-11 | $4.01 | 712,700 |
| 2026-06-10 | $3.87 | 501,200 |
| 2026-06-09 | $3.91 | 532,400 |
| 2026-06-08 | $3.88 | 641,200 |
| 2026-06-05 | $3.91 | 560,000 |
| 2026-06-04 | $4.25 | 520,300 |
| 2026-06-03 | $4.20 | 629,100 |
| 2026-06-02 | $4.05 | 492,500 |
| 2026-06-01 | $4.14 | 555,600 |
| 2026-05-29 | $4.16 | 597,000 |
| 2026-05-28 | $4.21 | 469,400 |
| 2026-05-27 | $4.38 | 674,400 |
| 2026-05-26 | $4.47 | 1,052,500 |
About MacroGenics, Inc.
MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics for the treatment of cancer in the United States. The company's product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical trials, as well as for the treatment of platinum-resistant ovarian cancer and clear cell gynecologic cancer which has completed phase 1 clinical trial; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload; MGC028, an antibody-drug conjugates (ADC) that targets ADAM9 and delivers a novel TOP1i-based linker-payload for the treatment of solid tumors, which is in phase 1 clinical trials; MGC030, a ADC molecule that targets an undisclosed antigen expressed across several solid tumors, which is in preclinical trials. It is also developing T-cell engager programs. The company has collaborations with TerSera Therapeutics LLC; Incyte Corporation; and Gilead Sciences, Inc. MacroGenics, Inc. was incorporated in 2000 and is headquartered in Rockville, Maryland.
đ° Latest News
No news articles available at the moment. Check back later for updates on MGNX.
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $36,009,000 | $12,299,000 | $8,222,000 | $7,384,000 |
| Cost Of Revenue | $36,009,000 | $12,299,000 | $8,222,000 | $7,384,000 |
| Total Revenue | $149,500,000 | $149,962,000 | $58,749,000 | $150,018,000 |
| Operating Revenue | $149,500,000 | $149,962,000 | $58,749,000 | $150,018,000 |
| Expenses | ||||
| Interest Expense | $8,508,000 | $1,115,000 | $1,430,000 | $0 |
| Total Expenses | $222,341,000 | $260,540,000 | $226,993,000 | $271,436,000 |
| Net Non Operating Interest Income Expense | $-2,451,000 | $8,306,000 | $8,256,000 | $1,660,000 |
| Interest Expense Non Operating | $8,508,000 | $1,115,000 | $1,430,000 | $0 |
| Operating Expense | $186,332,000 | $248,241,000 | $218,771,000 | $264,052,000 |
| Other Income Expense | - | $36,250,000 | $150,930,000 | $1,660,000 |
| Other Operating Expenses | - | $-1,623,000 | $-1,556,000 | $-1,923,000 |
| Other Non Operating Income Expenses | - | - | - | $1,660,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-74,620,000 | $-66,966,000 | $-9,058,000 | $-119,758,000 |
| Net Interest Income | $-2,451,000 | $8,306,000 | $8,256,000 | $1,660,000 |
| Interest Income | $6,057,000 | $9,421,000 | $9,686,000 | $1,660,000 |
| Normalized Income | $-74,620,000 | $-95,603,500 | $-159,988,000 | $-119,758,000 |
| Net Income From Continuing And Discontinued Operation | $-74,620,000 | $-66,966,000 | $-9,058,000 | $-119,758,000 |
| Total Operating Income As Reported | $-72,841,000 | $-110,578,000 | $-168,244,000 | $-121,418,000 |
| Net Income Common Stockholders | $-74,620,000 | $-66,966,000 | $-9,058,000 | $-119,758,000 |
| Net Income | $-74,620,000 | $-66,966,000 | $-9,058,000 | $-119,758,000 |
| Net Income Including Noncontrolling Interests | $-74,620,000 | $-66,966,000 | $-9,058,000 | $-119,758,000 |
| Net Income Continuous Operations | $-74,620,000 | $-66,966,000 | $-9,058,000 | $-119,758,000 |
| Pretax Income | $-75,292,000 | $-66,022,000 | $-9,058,000 | $-119,758,000 |
| Special Income Charges | $0 | $36,250,000 | $150,930,000 | $0 |
| Interest Income Non Operating | $6,057,000 | $9,421,000 | $9,686,000 | $1,660,000 |
| Operating Income | $-72,841,000 | $-110,578,000 | $-168,244,000 | $-121,418,000 |
| Gross Profit | $113,491,000 | $137,663,000 | $50,527,000 | $142,634,000 |
| Per Share | ||||
| Diluted EPS | $-1.18 | $-1.07 | $-0.15 | $-1.95 |
| Basic EPS | $-1.18 | $-1.07 | $-0.15 | $-1.95 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $7,612,500 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-59,612,000 | $-93,617,000 | $-148,913,000 | $-107,893,000 |
| Total Unusual Items | $0 | $36,250,000 | $150,930,000 | $0 |
| Total Unusual Items Excluding Goodwill | $0 | $36,250,000 | $150,930,000 | $0 |
| Reconciled Depreciation | $7,172,000 | $7,540,000 | $9,645,000 | $11,865,000 |
| EBITDA (Bullshit earnings) | $-59,612,000 | $-57,367,000 | $2,017,000 | $-107,893,000 |
| EBIT | $-66,784,000 | $-64,907,000 | $-7,628,000 | $-119,758,000 |
| Diluted Average Shares | $63,155,096 | $62,621,185 | $61,929,198 | $61,433,124 |
| Basic Average Shares | $63,155,096 | $62,621,185 | $61,929,198 | $61,433,124 |
| Diluted NI Availto Com Stockholders | $-74,620,000 | $-66,966,000 | $-9,058,000 | $-119,758,000 |
| Tax Provision | $-672,000 | $944,000 | $0 | $0 |
| Gain On Sale Of Business | $0 | $36,250,000 | $150,930,000 | $0 |
| Research And Development | $147,172,000 | $177,194,000 | $166,583,000 | $207,026,000 |
| Selling General And Administration | $39,160,000 | $71,047,000 | $52,188,000 | $58,949,000 |
Fetched: 2026-06-20
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $55,591,000 | $116,057,000 | $152,613,000 | $142,013,000 |
| Total Assets | $256,846,000 | $261,655,000 | $298,418,000 | $280,468,000 |
| Total Non Current Assets | $36,905,000 | $44,165,000 | $47,079,000 | $58,288,000 |
| Other Non Current Assets | $1,385,000 | $1,556,000 | $1,386,000 | $1,378,000 |
| Current Assets | $219,941,000 | $217,490,000 | $251,339,000 | $222,180,000 |
| Other Current Assets | $8,745,000 | $11,514,000 | $9,946,000 | $10,161,000 |
| Inventory | $7,910,000 | $0 | $1,221,000 | $1,451,000 |
| Receivables | $13,373,000 | $4,309,000 | $10,367,000 | $56,222,000 |
| Accounts Receivable | $13,373,000 | $4,309,000 | $10,367,000 | $56,222,000 |
| Cash Cash Equivalents And Short Term Investments | $189,913,000 | $201,667,000 | $229,805,000 | $154,346,000 |
| Cash And Cash Equivalents | $57,217,000 | $182,840,000 | $100,956,000 | $108,884,000 |
| Prepaid Assets | - | - | - | - |
| Debt | ||||
| Total Debt | $36,762,000 | $37,461,000 | $33,971,000 | $34,832,000 |
| Long Term Debt And Capital Lease Obligation | $31,585,000 | $32,597,000 | $30,196,000 | $30,106,000 |
| Current Debt And Capital Lease Obligation | $5,177,000 | $4,864,000 | $3,775,000 | $4,726,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $201,255,000 | $145,598,000 | $145,805,000 | $138,455,000 |
| Total Non Current Liabilities Net Minority Interest | $158,140,000 | $90,068,000 | $89,697,000 | $89,844,000 |
| Other Non Current Liabilities | $71,052,000 | $1,968,000 | $258,000 | $258,000 |
| Non Current Deferred Liabilities | $55,503,000 | $55,503,000 | $59,243,000 | $59,480,000 |
| Current Liabilities | $43,115,000 | $55,530,000 | $56,108,000 | $48,611,000 |
| Current Deferred Liabilities | $10,921,000 | $16,319,000 | $21,651,000 | $9,988,000 |
| Payables And Accrued Expenses | $27,017,000 | $34,347,000 | $30,682,000 | $33,897,000 |
| Payables | $4,787,000 | $5,013,000 | $6,443,000 | $4,899,000 |
| Accounts Payable | $4,787,000 | $5,013,000 | $6,443,000 | $4,899,000 |
| Equity | ||||
| Common Stock Equity | $55,591,000 | $116,057,000 | $152,613,000 | $142,013,000 |
| Total Equity Gross Minority Interest | $55,591,000 | $116,057,000 | $152,613,000 | $142,013,000 |
| Stockholders Equity | $55,591,000 | $116,057,000 | $152,613,000 | $142,013,000 |
| Gains Losses Not Affecting Retained Earnings | $32,000 | $4,000 | $-6,000 | $-5,000 |
| Other Equity Adjustments | $32,000 | $4,000 | $-6,000 | $-5,000 |
| Retained Earnings | $-1,244,338,000 | $-1,169,718,000 | $-1,102,752,000 | $-1,093,694,000 |
| Other | ||||
| Ordinary Shares Number | $63,318,613 | $62,819,857 | $62,070,627 | $61,701,467 |
| Share Issued | $63,318,613 | $62,819,857 | $62,070,627 | $61,701,467 |
| Tangible Book Value | $55,591,000 | $116,057,000 | $152,613,000 | $142,013,000 |
| Invested Capital | $55,591,000 | $116,057,000 | $152,613,000 | $142,013,000 |
| Working Capital | $176,826,000 | $161,960,000 | $195,231,000 | $173,569,000 |
| Capital Lease Obligations | $36,762,000 | $37,461,000 | $33,971,000 | $34,832,000 |
| Total Capitalization | $55,591,000 | $116,057,000 | $152,613,000 | $142,013,000 |
| Additional Paid In Capital | $1,299,264,000 | $1,285,143,000 | $1,254,750,000 | $1,235,095,000 |
| Capital Stock | $633,000 | $628,000 | $621,000 | $617,000 |
| Common Stock | $633,000 | $628,000 | $621,000 | $617,000 |
| Non Current Deferred Revenue | $55,503,000 | $55,503,000 | $59,243,000 | $59,480,000 |
| Long Term Capital Lease Obligation | $31,585,000 | $32,597,000 | $30,196,000 | $30,106,000 |
| Current Deferred Revenue | $10,921,000 | $16,319,000 | $21,651,000 | $9,988,000 |
| Current Capital Lease Obligation | $5,177,000 | $4,864,000 | $3,775,000 | $4,726,000 |
| Current Accrued Expenses | $22,230,000 | $29,334,000 | $24,239,000 | $28,998,000 |
| Net PPE | $35,520,000 | $42,609,000 | $45,693,000 | $56,910,000 |
| Accumulated Depreciation | $-95,807,000 | $-88,687,000 | $-88,394,000 | $-84,085,000 |
| Gross PPE | $131,327,000 | $131,296,000 | $134,087,000 | $140,995,000 |
| Leases | $45,023,000 | $44,097,000 | $48,620,000 | $52,974,000 |
| Construction In Progress | $371,000 | $1,216,000 | $1,112,000 | $356,000 |
| Other Properties | $70,157,000 | $70,649,000 | $70,298,000 | $73,809,000 |
| Machinery Furniture Equipment | $15,776,000 | $15,334,000 | $14,057,000 | $13,856,000 |
| Properties | $0 | $0 | $0 | $0 |
| Other Inventories | $10,000 | - | - | - |
| Raw Materials | $7,900,000 | - | - | - |
| Other Short Term Investments | $132,696,000 | $18,827,000 | $128,849,000 | $45,462,000 |
| Treasury Shares Number | - | - | $0 | - |
| Finished Goods | - | - | $960,000 | $1,042,000 |
| Work In Process | - | - | $261,000 | $409,000 |
Fetched: 2026-06-20
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-82,954,000 | $-72,079,000 | $-79,969,000 | $-90,582,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-81,040,000 | $-68,373,000 | $-78,205,000 | $-86,959,000 |
| Cash Flow From Continuing Operating Activities | $-81,040,000 | $-68,373,000 | $-78,205,000 | $-86,959,000 |
| Operating Gains Losses | $-10,000 | $-36,307,000 | $-150,819,000 | - |
| Investing Activities | ||||
| Capital Expenditure | $-1,914,000 | $-3,706,000 | $-1,764,000 | $-3,623,000 |
| Investing Cash Flow | $-114,097,000 | $149,297,000 | $-80,084,000 | $70,715,000 |
| Cash Flow From Continuing Investing Activities | $-114,097,000 | $149,297,000 | $-80,084,000 | $70,715,000 |
| Net Other Investing Changes | - | $40,000,000 | - | - |
| Financing Activities | ||||
| Issuance Of Capital Stock | $0 | $0 | $616,000 | $1,085,000 |
| Financing Cash Flow | $69,514,000 | $960,000 | $150,361,000 | $1,659,000 |
| Cash Flow From Continuing Financing Activities | $69,514,000 | $960,000 | $150,361,000 | $1,659,000 |
| Net Other Financing Charges | $69,385,000 | $-2,475,000 | $149,192,000 | - |
| Net Common Stock Issuance | $0 | $0 | $616,000 | $1,085,000 |
| Common Stock Issuance | $0 | $0 | $616,000 | $1,085,000 |
| Other | ||||
| End Cash Position | $57,217,000 | $182,840,000 | $100,956,000 | $108,884,000 |
| Beginning Cash Position | $182,840,000 | $100,956,000 | $108,884,000 | $123,469,000 |
| Changes In Cash | $-125,623,000 | $81,884,000 | $-7,928,000 | $-14,585,000 |
| Proceeds From Stock Option Exercised | $129,000 | $3,435,000 | $553,000 | $574,000 |
| Net Investment Purchase And Sale | $-112,194,000 | $112,843,000 | $-78,384,000 | $74,338,000 |
| Sale Of Investment | $96,142,000 | $190,025,000 | $161,299,000 | $194,940,000 |
| Purchase Of Investment | $-208,336,000 | $-77,182,000 | $-239,683,000 | $-120,602,000 |
| Net PPE Purchase And Sale | $-1,903,000 | $-3,546,000 | $-1,700,000 | $-3,623,000 |
| Sale Of PPE | $11,000 | $160,000 | $64,000 | $0 |
| Purchase Of PPE | $-1,914,000 | $-3,706,000 | $-1,764,000 | $-3,623,000 |
| Change In Working Capital | $-28,331,000 | $1,392,000 | $53,316,000 | $-6,130,000 |
| Change In Other Working Capital | $-5,398,000 | $-9,584,000 | $11,419,000 | $34,776,000 |
| Change In Other Current Liabilities | $-1,615,000 | $5,200,000 | $-861,000 | $9,364,000 |
| Change In Payables And Accrued Expense | $-7,114,000 | $3,473,000 | $-3,542,000 | $-15,498,000 |
| Change In Accrued Expense | $-6,834,000 | $5,003,000 | $-4,823,000 | $-4,638,000 |
| Change In Payable | $-280,000 | $-1,530,000 | $1,281,000 | $-10,860,000 |
| Change In Account Payable | $-280,000 | $-1,530,000 | $1,281,000 | $-10,860,000 |
| Change In Prepaid Assets | $2,769,000 | $-1,567,000 | $215,000 | $11,009,000 |
| Change In Inventory | $-7,910,000 | $-2,188,000 | $230,000 | $55,000 |
| Change In Receivables | $-9,063,000 | $6,058,000 | $45,855,000 | $-45,836,000 |
| Changes In Account Receivables | $-9,063,000 | $6,058,000 | $45,855,000 | $-45,836,000 |
| Other Non Cash Items | $2,111,000 | $-661,000 | $5,342,000 | $6,223,000 |
| Stock Based Compensation | $14,286,000 | $29,439,000 | $18,373,000 | $20,438,000 |
| Amortization Of Securities | $-1,648,000 | $-2,810,000 | $-5,004,000 | $403,000 |
| Depreciation Amortization Depletion | $7,172,000 | $7,540,000 | $9,645,000 | $11,865,000 |
| Depreciation And Amortization | $7,172,000 | $7,540,000 | $9,645,000 | $11,865,000 |
| Net Income From Continuing Operations | $-74,620,000 | $-66,966,000 | $-9,058,000 | $-119,758,000 |
| Income Tax Paid Supplemental Data | - | $944,000 | $0 | $0 |
| Change In Other Current Assets | - | - | $-7,000 | $-14,045,000 |
| Gain Loss On Investment Securities | - | - | $-150,930,000 | - |
Fetched: 2026-06-20